Click for best price
Multiple Sclerosis MS Drugs Market Size, Share 2024
This research report provides a comprehensive analysis of the Multiple Sclerosis (MS) Drugs market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Multiple Sclerosis (MS) Drugs market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Multiple Sclerosis (MS) Drugs, challenges faced by the industry, and potential opportunities for market players.
The global Multiple Sclerosis (MS) Drugs market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Multiple Sclerosis (MS) Drugs market presents opportunities for various stakeholders, including RRMS, SPMS. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Multiple Sclerosis (MS) Drugs market. Additionally, the growing consumer demand present avenues for market expansion.
The global Multiple Sclerosis (MS) Drugs market was valued at US$ million in 2023 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The research report on the Multiple Sclerosis (MS) Drugs market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Multiple Sclerosis (MS) Drugs market.
Market Overview: The report provides a comprehensive overview of the Multiple Sclerosis (MS) Drugs market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Copaxone (Glatiramer Acetate, Copolymer 1), Novantrone (Mitoxantrone)), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Multiple Sclerosis (MS) Drugs market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Multiple Sclerosis (MS) Drugs market's trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Multiple Sclerosis (MS) Drugs market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Multiple Sclerosis (MS) Drugs market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Multiple Sclerosis (MS) Drugs market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Multiple Sclerosis (MS) Drugs market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Multiple Sclerosis (MS) Drugs, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Multiple Sclerosis (MS) Drugs market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Multiple Sclerosis (MS) Drugs market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Copaxone (Glatiramer Acetate, Copolymer 1)
Novantrone (Mitoxantrone)
Gilenya (Fingolimod, Fty720)
Aubagio (Teriflunomide)
Tecfidera (Dimethyl Fumarate)
Firategrast (Sb683699, T-0047)
Siponimod (Baf312)
Others
Market segment by Application
RRMS
SPMS
PPMS
PRMS
Global Multiple Sclerosis (MS) Drugs Market Segment Percentages, By Region and Country, 2023 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Bayer AG
Bayhill Therapeutics
Biogen Idec
Cinnagen
Daiichi Sankyo
Eli Lilly
Fast Forward Llc
Antisense Therapeutics
Apitope
Five Prime Therapeutics
Genmab
Artielle Immunotherapeutics
Genzyme
Glaxosmithkline
Gw Pharmaceuticals
Innate Immunotherapeutics
Outline of Major Chapters:
Chapter 1: Introduces the definition of Multiple Sclerosis (MS) Drugs, market overview.
Chapter 2: Global Multiple Sclerosis (MS) Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Multiple Sclerosis (MS) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Multiple Sclerosis (MS) Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Multiple Sclerosis (MS) Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Multiple Sclerosis (MS) Drugs Market, Global Outlook and Forecast 2024-2030 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2023 |
| Forecast Year |
2031 |
| Number of Pages |
144 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Multiple Sclerosis (MS) Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Multiple Sclerosis (MS) Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Multiple Sclerosis (MS) Drugs Overall Market Size
2.1 Global Multiple Sclerosis (MS) Drugs Market Size: 2023 VS 2030
2.2 Global Multiple Sclerosis (MS) Drugs Revenue, Prospects & Forecasts: 2019-2030
2.3 Global Multiple Sclerosis (MS) Drugs Sales: 2019-2030
3 Company Landscape
3.1 Top Multiple Sclerosis (MS) Drugs Players in Global Market
3.2 Top Global Multiple Sclerosis (MS) Drugs Companies Ranked by Revenue
3.3 Global Multiple Sclerosis (MS) Drugs Revenue by Companies
3.4 Global Multiple Sclerosis (MS) Drugs Sales by Companies
3.5 Global Multiple Sclerosis (MS) Drugs Price by Manufacturer (2019-2024)
3.6 Top 3 and Top 5 Multiple Sclerosis (MS) Drugs Companies in Global Market, by Revenue in 2023
3.7 Global Manufacturers Multiple Sclerosis (MS) Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Multiple Sclerosis (MS) Drugs Players in Global Market
3.8.1 List of Global Tier 1 Multiple Sclerosis (MS) Drugs Companies
3.8.2 List of Global Tier 2 and Tier 3 Multiple Sclerosis (MS) Drugs Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Multiple Sclerosis (MS) Drugs Market Size Markets, 2023 & 2030
4.1.2 Copaxone (Glatiramer Acetate, Copolymer 1)
4.1.3 Novantrone (Mitoxantrone)
4.1.4 Gilenya (Fingolimod, Fty720)
4.1.5 Aubagio (Teriflunomide)
4.1.6 Tecfidera (Dimethyl Fumarate)
4.1.7 Firategrast (Sb683699, T-0047)
4.1.8 Siponimod (Baf312)
4.1.9 Others
4.2 By Type - Global Multiple Sclerosis (MS) Drugs Revenue & Forecasts
4.2.1 By Type - Global Multiple Sclerosis (MS) Drugs Revenue, 2019-2024
4.2.2 By Type - Global Multiple Sclerosis (MS) Drugs Revenue, 2025-2030
4.2.3 By Type - Global Multiple Sclerosis (MS) Drugs Revenue Market Share, 2019-2030
4.3 By Type - Global Multiple Sclerosis (MS) Drugs Sales & Forecasts
4.3.1 By Type - Global Multiple Sclerosis (MS) Drugs Sales, 2019-2024
4.3.2 By Type - Global Multiple Sclerosis (MS) Drugs Sales, 2025-2030
4.3.3 By Type - Global Multiple Sclerosis (MS) Drugs Sales Market Share, 2019-2030
4.4 By Type - Global Multiple Sclerosis (MS) Drugs Price (Manufacturers Selling Prices), 2019-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Multiple Sclerosis (MS) Drugs Market Size, 2023 & 2030
5.1.2 RRMS
5.1.3 SPMS
5.1.4 PPMS
5.1.5 PRMS
5.2 By Application - Global Multiple Sclerosis (MS) Drugs Revenue & Forecasts
5.2.1 By Application - Global Multiple Sclerosis (MS) Drugs Revenue, 2019-2024
5.2.2 By Application - Global Multiple Sclerosis (MS) Drugs Revenue, 2025-2030
5.2.3 By Application - Global Multiple Sclerosis (MS) Drugs Revenue Market Share, 2019-2030
5.3 By Application - Global Multiple Sclerosis (MS) Drugs Sales & Forecasts
5.3.1 By Application - Global Multiple Sclerosis (MS) Drugs Sales, 2019-2024
5.3.2 By Application - Global Multiple Sclerosis (MS) Drugs Sales, 2025-2030
5.3.3 By Application - Global Multiple Sclerosis (MS) Drugs Sales Market Share, 2019-2030
5.4 By Application - Global Multiple Sclerosis (MS) Drugs Price (Manufacturers Selling Prices), 2019-2030
6 Sights by Region
6.1 By Region - Global Multiple Sclerosis (MS) Drugs Market Size, 2023 & 2030
6.2 By Region - Global Multiple Sclerosis (MS) Drugs Revenue & Forecasts
6.2.1 By Region - Global Multiple Sclerosis (MS) Drugs Revenue, 2019-2024
6.2.2 By Region - Global Multiple Sclerosis (MS) Drugs Revenue, 2025-2030
6.2.3 By Region - Global Multiple Sclerosis (MS) Drugs Revenue Market Share, 2019-2030
6.3 By Region - Global Multiple Sclerosis (MS) Drugs Sales & Forecasts
6.3.1 By Region - Global Multiple Sclerosis (MS) Drugs Sales, 2019-2024
6.3.2 By Region - Global Multiple Sclerosis (MS) Drugs Sales, 2025-2030
6.3.3 By Region - Global Multiple Sclerosis (MS) Drugs Sales Market Share, 2019-2030
6.4 North America
6.4.1 By Country - North America Multiple Sclerosis (MS) Drugs Revenue, 2019-2030
6.4.2 By Country - North America Multiple Sclerosis (MS) Drugs Sales, 2019-2030
6.4.3 US Multiple Sclerosis (MS) Drugs Market Size, 2019-2030
6.4.4 Canada Multiple Sclerosis (MS) Drugs Market Size, 2019-2030
6.4.5 Mexico Multiple Sclerosis (MS) Drugs Market Size, 2019-2030
6.5 Europe
6.5.1 By Country - Europe Multiple Sclerosis (MS) Drugs Revenue, 2019-2030
6.5.2 By Country - Europe Multiple Sclerosis (MS) Drugs Sales, 2019-2030
6.5.3 Germany Multiple Sclerosis (MS) Drugs Market Size, 2019-2030
6.5.4 France Multiple Sclerosis (MS) Drugs Market Size, 2019-2030
6.5.5 U.K. Multiple Sclerosis (MS) Drugs Market Size, 2019-2030
6.5.6 Italy Multiple Sclerosis (MS) Drugs Market Size, 2019-2030
6.5.7 Russia Multiple Sclerosis (MS) Drugs Market Size, 2019-2030
6.5.8 Nordic Countries Multiple Sclerosis (MS) Drugs Market Size, 2019-2030
6.5.9 Benelux Multiple Sclerosis (MS) Drugs Market Size, 2019-2030
6.6 Asia
6.6.1 By Region - Asia Multiple Sclerosis (MS) Drugs Revenue, 2019-2030
6.6.2 By Region - Asia Multiple Sclerosis (MS) Drugs Sales, 2019-2030
6.6.3 China Multiple Sclerosis (MS) Drugs Market Size, 2019-2030
6.6.4 Japan Multiple Sclerosis (MS) Drugs Market Size, 2019-2030
6.6.5 South Korea Multiple Sclerosis (MS) Drugs Market Size, 2019-2030
6.6.6 Southeast Asia Multiple Sclerosis (MS) Drugs Market Size, 2019-2030
6.6.7 India Multiple Sclerosis (MS) Drugs Market Size, 2019-2030
6.7 South America
6.7.1 By Country - South America Multiple Sclerosis (MS) Drugs Revenue, 2019-2030
6.7.2 By Country - South America Multiple Sclerosis (MS) Drugs Sales, 2019-2030
6.7.3 Brazil Multiple Sclerosis (MS) Drugs Market Size, 2019-2030
6.7.4 Argentina Multiple Sclerosis (MS) Drugs Market Size, 2019-2030
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Multiple Sclerosis (MS) Drugs Revenue, 2019-2030
6.8.2 By Country - Middle East & Africa Multiple Sclerosis (MS) Drugs Sales, 2019-2030
6.8.3 Turkey Multiple Sclerosis (MS) Drugs Market Size, 2019-2030
6.8.4 Israel Multiple Sclerosis (MS) Drugs Market Size, 2019-2030
6.8.5 Saudi Arabia Multiple Sclerosis (MS) Drugs Market Size, 2019-2030
6.8.6 UAE Multiple Sclerosis (MS) Drugs Market Size, 2019-2030
7 Manufacturers & Brands Profiles
7.1 Bayer AG
7.1.1 Bayer AG Company Summary
7.1.2 Bayer AG Business Overview
7.1.3 Bayer AG Multiple Sclerosis (MS) Drugs Major Product Offerings
7.1.4 Bayer AG Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2019-2024)
7.1.5 Bayer AG Key News & Latest Developments
7.2 Bayhill Therapeutics
7.2.1 Bayhill Therapeutics Company Summary
7.2.2 Bayhill Therapeutics Business Overview
7.2.3 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Major Product Offerings
7.2.4 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2019-2024)
7.2.5 Bayhill Therapeutics Key News & Latest Developments
7.3 Biogen Idec
7.3.1 Biogen Idec Company Summary
7.3.2 Biogen Idec Business Overview
7.3.3 Biogen Idec Multiple Sclerosis (MS) Drugs Major Product Offerings
7.3.4 Biogen Idec Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2019-2024)
7.3.5 Biogen Idec Key News & Latest Developments
7.4 Cinnagen
7.4.1 Cinnagen Company Summary
7.4.2 Cinnagen Business Overview
7.4.3 Cinnagen Multiple Sclerosis (MS) Drugs Major Product Offerings
7.4.4 Cinnagen Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2019-2024)
7.4.5 Cinnagen Key News & Latest Developments
7.5 Daiichi Sankyo
7.5.1 Daiichi Sankyo Company Summary
7.5.2 Daiichi Sankyo Business Overview
7.5.3 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Major Product Offerings
7.5.4 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2019-2024)
7.5.5 Daiichi Sankyo Key News & Latest Developments
7.6 Eli Lilly
7.6.1 Eli Lilly Company Summary
7.6.2 Eli Lilly Business Overview
7.6.3 Eli Lilly Multiple Sclerosis (MS) Drugs Major Product Offerings
7.6.4 Eli Lilly Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2019-2024)
7.6.5 Eli Lilly Key News & Latest Developments
7.7 Fast Forward Llc
7.7.1 Fast Forward Llc Company Summary
7.7.2 Fast Forward Llc Business Overview
7.7.3 Fast Forward Llc Multiple Sclerosis (MS) Drugs Major Product Offerings
7.7.4 Fast Forward Llc Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2019-2024)
7.7.5 Fast Forward Llc Key News & Latest Developments
7.8 Antisense Therapeutics
7.8.1 Antisense Therapeutics Company Summary
7.8.2 Antisense Therapeutics Business Overview
7.8.3 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Major Product Offerings
7.8.4 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2019-2024)
7.8.5 Antisense Therapeutics Key News & Latest Developments
7.9 Apitope
7.9.1 Apitope Company Summary
7.9.2 Apitope Business Overview
7.9.3 Apitope Multiple Sclerosis (MS) Drugs Major Product Offerings
7.9.4 Apitope Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2019-2024)
7.9.5 Apitope Key News & Latest Developments
7.10 Five Prime Therapeutics
7.10.1 Five Prime Therapeutics Company Summary
7.10.2 Five Prime Therapeutics Business Overview
7.10.3 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Major Product Offerings
7.10.4 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2019-2024)
7.10.5 Five Prime Therapeutics Key News & Latest Developments
7.11 Genmab
7.11.1 Genmab Company Summary
7.11.2 Genmab Business Overview
7.11.3 Genmab Multiple Sclerosis (MS) Drugs Major Product Offerings
7.11.4 Genmab Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2019-2024)
7.11.5 Genmab Key News & Latest Developments
7.12 Artielle Immunotherapeutics
7.12.1 Artielle Immunotherapeutics Company Summary
7.12.2 Artielle Immunotherapeutics Business Overview
7.12.3 Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Major Product Offerings
7.12.4 Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2019-2024)
7.12.5 Artielle Immunotherapeutics Key News & Latest Developments
7.13 Genzyme
7.13.1 Genzyme Company Summary
7.13.2 Genzyme Business Overview
7.13.3 Genzyme Multiple Sclerosis (MS) Drugs Major Product Offerings
7.13.4 Genzyme Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2019-2024)
7.13.5 Genzyme Key News & Latest Developments
7.14 Glaxosmithkline
7.14.1 Glaxosmithkline Company Summary
7.14.2 Glaxosmithkline Business Overview
7.14.3 Glaxosmithkline Multiple Sclerosis (MS) Drugs Major Product Offerings
7.14.4 Glaxosmithkline Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2019-2024)
7.14.5 Glaxosmithkline Key News & Latest Developments
7.15 Gw Pharmaceuticals
7.15.1 Gw Pharmaceuticals Company Summary
7.15.2 Gw Pharmaceuticals Business Overview
7.15.3 Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Major Product Offerings
7.15.4 Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2019-2024)
7.15.5 Gw Pharmaceuticals Key News & Latest Developments
7.16 Innate Immunotherapeutics
7.16.1 Innate Immunotherapeutics Company Summary
7.16.2 Innate Immunotherapeutics Business Overview
7.16.3 Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Major Product Offerings
7.16.4 Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales and Revenue in Global (2019-2024)
7.16.5 Innate Immunotherapeutics Key News & Latest Developments
8 Global Multiple Sclerosis (MS) Drugs Production Capacity, Analysis
8.1 Global Multiple Sclerosis (MS) Drugs Production Capacity, 2019-2030
8.2 Multiple Sclerosis (MS) Drugs Production Capacity of Key Manufacturers in Global Market
8.3 Global Multiple Sclerosis (MS) Drugs Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Multiple Sclerosis (MS) Drugs Supply Chain Analysis
10.1 Multiple Sclerosis (MS) Drugs Industry Value Chain
10.2 Multiple Sclerosis (MS) Drugs Upstream Market
10.3 Multiple Sclerosis (MS) Drugs Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Multiple Sclerosis (MS) Drugs Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Key Players of Multiple Sclerosis (MS) Drugs in Global Market
Table 2. Top Multiple Sclerosis (MS) Drugs Players in Global Market, Ranking by Revenue (2023)
Table 3. Global Multiple Sclerosis (MS) Drugs Revenue by Companies, (US$, Mn), 2019-2024
Table 4. Global Multiple Sclerosis (MS) Drugs Revenue Share by Companies, 2019-2024
Table 5. Global Multiple Sclerosis (MS) Drugs Sales by Companies, (K Pcs), 2019-2024
Table 6. Global Multiple Sclerosis (MS) Drugs Sales Share by Companies, 2019-2024
Table 7. Key Manufacturers Multiple Sclerosis (MS) Drugs Price (2019-2024) & (USD/Pcs)
Table 8. Global Manufacturers Multiple Sclerosis (MS) Drugs Product Type
Table 9. List of Global Tier 1 Multiple Sclerosis (MS) Drugs Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Multiple Sclerosis (MS) Drugs Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 11. By Type ? Global Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2023 & 2030
Table 12. By Type - Global Multiple Sclerosis (MS) Drugs Revenue (US$, Mn), 2019-2024
Table 13. By Type - Global Multiple Sclerosis (MS) Drugs Revenue (US$, Mn), 2025-2030
Table 14. By Type - Global Multiple Sclerosis (MS) Drugs Sales (K Pcs), 2019-2024
Table 15. By Type - Global Multiple Sclerosis (MS) Drugs Sales (K Pcs), 2025-2030
Table 16. By Application ? Global Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2023 & 2030
Table 17. By Application - Global Multiple Sclerosis (MS) Drugs Revenue (US$, Mn), 2019-2024
Table 18. By Application - Global Multiple Sclerosis (MS) Drugs Revenue (US$, Mn), 2025-2030
Table 19. By Application - Global Multiple Sclerosis (MS) Drugs Sales (K Pcs), 2019-2024
Table 20. By Application - Global Multiple Sclerosis (MS) Drugs Sales (K Pcs), 2025-2030
Table 21. By Region ? Global Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2023 VS 2030
Table 22. By Region - Global Multiple Sclerosis (MS) Drugs Revenue (US$, Mn), 2019-2024
Table 23. By Region - Global Multiple Sclerosis (MS) Drugs Revenue (US$, Mn), 2025-2030
Table 24. By Region - Global Multiple Sclerosis (MS) Drugs Sales (K Pcs), 2019-2024
Table 25. By Region - Global Multiple Sclerosis (MS) Drugs Sales (K Pcs), 2025-2030
Table 26. By Country - North America Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2019-2024
Table 27. By Country - North America Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2025-2030
Table 28. By Country - North America Multiple Sclerosis (MS) Drugs Sales, (K Pcs), 2019-2024
Table 29. By Country - North America Multiple Sclerosis (MS) Drugs Sales, (K Pcs), 2025-2030
Table 30. By Country - Europe Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2019-2024
Table 31. By Country - Europe Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2025-2030
Table 32. By Country - Europe Multiple Sclerosis (MS) Drugs Sales, (K Pcs), 2019-2024
Table 33. By Country - Europe Multiple Sclerosis (MS) Drugs Sales, (K Pcs), 2025-2030
Table 34. By Region - Asia Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2019-2024
Table 35. By Region - Asia Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2025-2030
Table 36. By Region - Asia Multiple Sclerosis (MS) Drugs Sales, (K Pcs), 2019-2024
Table 37. By Region - Asia Multiple Sclerosis (MS) Drugs Sales, (K Pcs), 2025-2030
Table 38. By Country - South America Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2019-2024
Table 39. By Country - South America Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2025-2030
Table 40. By Country - South America Multiple Sclerosis (MS) Drugs Sales, (K Pcs), 2019-2024
Table 41. By Country - South America Multiple Sclerosis (MS) Drugs Sales, (K Pcs), 2025-2030
Table 42. By Country - Middle East & Africa Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2019-2024
Table 43. By Country - Middle East & Africa Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2025-2030
Table 44. By Country - Middle East & Africa Multiple Sclerosis (MS) Drugs Sales, (K Pcs), 2019-2024
Table 45. By Country - Middle East & Africa Multiple Sclerosis (MS) Drugs Sales, (K Pcs), 2025-2030
Table 46. Bayer AG Company Summary
Table 47. Bayer AG Multiple Sclerosis (MS) Drugs Product Offerings
Table 48. Bayer AG Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 49. Bayer AG Key News & Latest Developments
Table 50. Bayhill Therapeutics Company Summary
Table 51. Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Product Offerings
Table 52. Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 53. Bayhill Therapeutics Key News & Latest Developments
Table 54. Biogen Idec Company Summary
Table 55. Biogen Idec Multiple Sclerosis (MS) Drugs Product Offerings
Table 56. Biogen Idec Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 57. Biogen Idec Key News & Latest Developments
Table 58. Cinnagen Company Summary
Table 59. Cinnagen Multiple Sclerosis (MS) Drugs Product Offerings
Table 60. Cinnagen Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 61. Cinnagen Key News & Latest Developments
Table 62. Daiichi Sankyo Company Summary
Table 63. Daiichi Sankyo Multiple Sclerosis (MS) Drugs Product Offerings
Table 64. Daiichi Sankyo Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 65. Daiichi Sankyo Key News & Latest Developments
Table 66. Eli Lilly Company Summary
Table 67. Eli Lilly Multiple Sclerosis (MS) Drugs Product Offerings
Table 68. Eli Lilly Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 69. Eli Lilly Key News & Latest Developments
Table 70. Fast Forward Llc Company Summary
Table 71. Fast Forward Llc Multiple Sclerosis (MS) Drugs Product Offerings
Table 72. Fast Forward Llc Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 73. Fast Forward Llc Key News & Latest Developments
Table 74. Antisense Therapeutics Company Summary
Table 75. Antisense Therapeutics Multiple Sclerosis (MS) Drugs Product Offerings
Table 76. Antisense Therapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 77. Antisense Therapeutics Key News & Latest Developments
Table 78. Apitope Company Summary
Table 79. Apitope Multiple Sclerosis (MS) Drugs Product Offerings
Table 80. Apitope Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 81. Apitope Key News & Latest Developments
Table 82. Five Prime Therapeutics Company Summary
Table 83. Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Product Offerings
Table 84. Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 85. Five Prime Therapeutics Key News & Latest Developments
Table 86. Genmab Company Summary
Table 87. Genmab Multiple Sclerosis (MS) Drugs Product Offerings
Table 88. Genmab Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 89. Genmab Key News & Latest Developments
Table 90. Artielle Immunotherapeutics Company Summary
Table 91. Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Offerings
Table 92. Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 93. Artielle Immunotherapeutics Key News & Latest Developments
Table 94. Genzyme Company Summary
Table 95. Genzyme Multiple Sclerosis (MS) Drugs Product Offerings
Table 96. Genzyme Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 97. Genzyme Key News & Latest Developments
Table 98. Glaxosmithkline Company Summary
Table 99. Glaxosmithkline Multiple Sclerosis (MS) Drugs Product Offerings
Table 100. Glaxosmithkline Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 101. Glaxosmithkline Key News & Latest Developments
Table 102. Gw Pharmaceuticals Company Summary
Table 103. Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Product Offerings
Table 104. Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 105. Gw Pharmaceuticals Key News & Latest Developments
Table 106. Innate Immunotherapeutics Company Summary
Table 107. Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Offerings
Table 108. Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2019-2024)
Table 109. Innate Immunotherapeutics Key News & Latest Developments
Table 110. Multiple Sclerosis (MS) Drugs Production Capacity (K Pcs) of Key Manufacturers in Global Market, 2022-2024 (K Pcs)
Table 111. Global Multiple Sclerosis (MS) Drugs Capacity Market Share of Key Manufacturers, 2022-2024
Table 112. Global Multiple Sclerosis (MS) Drugs Production by Region, 2019-2024 (K Pcs)
Table 113. Global Multiple Sclerosis (MS) Drugs Production by Region, 2025-2030 (K Pcs)
Table 114. Multiple Sclerosis (MS) Drugs Market Opportunities & Trends in Global Market
Table 115. Multiple Sclerosis (MS) Drugs Market Drivers in Global Market
Table 116. Multiple Sclerosis (MS) Drugs Market Restraints in Global Market
Table 117. Multiple Sclerosis (MS) Drugs Raw Materials
Table 118. Multiple Sclerosis (MS) Drugs Raw Materials Suppliers in Global Market
Table 119. Typical Multiple Sclerosis (MS) Drugs Downstream
Table 120. Multiple Sclerosis (MS) Drugs Downstream Clients in Global Market
Table 121. Multiple Sclerosis (MS) Drugs Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Multiple Sclerosis (MS) Drugs Segment by Type in 2023
Figure 2. Multiple Sclerosis (MS) Drugs Segment by Application in 2023
Figure 3. Global Multiple Sclerosis (MS) Drugs Market Overview: 2023
Figure 4. Key Caveats
Figure 5. Global Multiple Sclerosis (MS) Drugs Market Size: 2023 VS 2030 (US$, Mn)
Figure 6. Global Multiple Sclerosis (MS) Drugs Revenue, 2019-2030 (US$, Mn)
Figure 7. Multiple Sclerosis (MS) Drugs Sales in Global Market: 2019-2030 (K Pcs)
Figure 8. The Top 3 and 5 Players Market Share by Multiple Sclerosis (MS) Drugs Revenue in 2023
Figure 9. By Type - Global Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2023 & 2030
Figure 10. By Type - Global Multiple Sclerosis (MS) Drugs Revenue Market Share, 2019-2030
Figure 11. By Type - Global Multiple Sclerosis (MS) Drugs Sales Market Share, 2019-2030
Figure 12. By Type - Global Multiple Sclerosis (MS) Drugs Price (USD/Pcs), 2019-2030
Figure 13. By Application - Global Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2023 & 2030
Figure 14. By Application - Global Multiple Sclerosis (MS) Drugs Revenue Market Share, 2019-2030
Figure 15. By Application - Global Multiple Sclerosis (MS) Drugs Sales Market Share, 2019-2030
Figure 16. By Application - Global Multiple Sclerosis (MS) Drugs Price (USD/Pcs), 2019-2030
Figure 17. By Region - Global Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2023 & 2030
Figure 18. By Region - Global Multiple Sclerosis (MS) Drugs Revenue Market Share, 2019 VS 2023 VS 2030
Figure 19. By Region - Global Multiple Sclerosis (MS) Drugs Revenue Market Share, 2019-2030
Figure 20. By Region - Global Multiple Sclerosis (MS) Drugs Sales Market Share, 2019-2030
Figure 21. By Country - North America Multiple Sclerosis (MS) Drugs Revenue Market Share, 2019-2030
Figure 22. By Country - North America Multiple Sclerosis (MS) Drugs Sales Market Share, 2019-2030
Figure 23. US Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2019-2030
Figure 24. Canada Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2019-2030
Figure 25. Mexico Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2019-2030
Figure 26. By Country - Europe Multiple Sclerosis (MS) Drugs Revenue Market Share, 2019-2030
Figure 27. By Country - Europe Multiple Sclerosis (MS) Drugs Sales Market Share, 2019-2030
Figure 28. Germany Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2019-2030
Figure 29. France Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2019-2030
Figure 30. U.K. Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2019-2030
Figure 31. Italy Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2019-2030
Figure 32. Russia Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2019-2030
Figure 33. Nordic Countries Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2019-2030
Figure 34. Benelux Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2019-2030
Figure 35. By Region - Asia Multiple Sclerosis (MS) Drugs Revenue Market Share, 2019-2030
Figure 36. By Region - Asia Multiple Sclerosis (MS) Drugs Sales Market Share, 2019-2030
Figure 37. China Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2019-2030
Figure 38. Japan Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2019-2030
Figure 39. South Korea Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2019-2030
Figure 40. Southeast Asia Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2019-2030
Figure 41. India Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2019-2030
Figure 42. By Country - South America Multiple Sclerosis (MS) Drugs Revenue Market Share, 2019-2030
Figure 43. By Country - South America Multiple Sclerosis (MS) Drugs Sales Market Share, 2019-2030
Figure 44. Brazil Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2019-2030
Figure 45. Argentina Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2019-2030
Figure 46. By Country - Middle East & Africa Multiple Sclerosis (MS) Drugs Revenue Market Share, 2019-2030
Figure 47. By Country - Middle East & Africa Multiple Sclerosis (MS) Drugs Sales Market Share, 2019-2030
Figure 48. Turkey Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2019-2030
Figure 49. Israel Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2019-2030
Figure 50. Saudi Arabia Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2019-2030
Figure 51. UAE Multiple Sclerosis (MS) Drugs Revenue, (US$, Mn), 2019-2030
Figure 52. Global Multiple Sclerosis (MS) Drugs Production Capacity (K Pcs), 2019-2030
Figure 53. The Percentage of Production Multiple Sclerosis (MS) Drugs by Region, 2023 VS 2030
Figure 54. Multiple Sclerosis (MS) Drugs Industry Value Chain
Figure 55. Marketing Channels
